The global AI in Oncology Market was valued at USD 4.22 billion in 2024 and is expected to reach USD 27.17 billion by 2032, growing at a CAGR of 26.23%. The U.S. market leads at USD 1.38 billion in 2024 and is projected to reach USD 8.26 billion by 2032, driven by rising cancer prevalence and demand for AI-based diagnostic insights.

AI-enabled oncology solutions are being used to accelerate drug discovery, predict treatment outcomes, and detect cancer at earlier stages. Segmentation shows hardware leading in 2024 at 40.2% market share, with breast cancer being the largest segment. Diagnostics is the most prevalent application, with hospitals dominating the end-use market at 49.3%.

Regional insights reveal North America leading the market in 2024, while Asia Pacific is the fastest-growing region. Recent developments include Azra AI expanding its oncology platform and Pathos AI securing USD 100 million for an AI platform focused on oncology drug discovery. Exclusive sections of the report offer key insights on cancer burden, AI adoption, investment trends, healthcare IT infrastructure, and cost reduction benchmarks. The AI in Oncology Market is projected to reach USD 27.17 billion by 2032, with a CAGR of 26.23% from 2025 to 2032. Key segments include component type, cancer type, application, and end use. Regional analysis covers North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

SNS Insider offers comprehensive market research and consulting services globally. With a focus on providing clients with up-to-date market data and insights, we utilize various techniques such as surveys, video talks, and focus groups to ensure informed decision-making in changing market conditions. Contact us for customized research inquiries.

Read more at GlobeNewswire: AI in Oncology Market Size to Accumulate Around USD 27.17